Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J R Soc Interface ; 7 Suppl 6: S707-16, 2010 Dec 06.
Article in English | MEDLINE | ID: mdl-20926429

ABSTRACT

Natural tissues are built of metabolites, soluble proteins and solid extracellular matrix components (largely fibrils) together with cells. These are configured in highly organized hierarchies of structure across length scales from nanometre to millimetre, with alignments that are dominated by anisotropies in their fibrillar matrix. If we are to successfully engineer tissues, these hierarchies need to be mimicked with an understanding of the interaction between them. In particular, the movement of different elements of the tissue (e.g. molecules, cells and bulk fluids) is controlled by matrix structures at distinct scales. We present three novel systems to introduce alignment of collagen fibrils, cells and growth factor gradients within a three-dimensional collagen scaffold using fluid flow, embossing and layering of construct. Importantly, these can be seen as different parts of the same hierarchy of three-dimensional structure, as they are all formed into dense collagen gels. Fluid flow aligns collagen fibrils at the nanoscale, embossed topographical features provide alignment cues at the microscale and introducing layered configuration to three-dimensional collagen scaffolds provides microscale- and mesoscale-aligned pathways for protein factor delivery as well as barriers to confine protein diffusion to specific spatial directions. These seemingly separate methods can be employed to increase complexity of simple extracellular matrix scaffolds, providing insight into new approaches to directly fabricate complex physical and chemical cues at different hierarchical scales, similar to those in natural tissues.


Subject(s)
Cell Culture Techniques , Collagen/ultrastructure , Nanomedicine/methods , Tissue Engineering/methods , Animals , Collagen/metabolism , Gels , Humans , Rats , Weights and Measures
2.
J Hand Surg Am ; 33(9): 1608-16, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18984345

ABSTRACT

PURPOSE: Dupuytren's disease is a common fibroproliferative condition of the hand characterized by fibrotic lesions (nodules and cords), leading to disability through progressive digital contracture. Although the etiology of the disease is poorly understood, recent evidence suggests that abnormal matrix metalloproteinase (MMP) activity may play a role in cell-mediated collagen contraction and tissue scarring. The aim of this study was to investigate the efficacy of ilomastat, a broad-spectrum MMP inhibitor, in an in vitro model of Dupuytren fibroblast-mediated contraction. METHODS: Nodule-derived and cord-derived fibroblasts were isolated from Dupuytren patients; carpal ligament-derived fibroblasts acted as control. Stress-release fibroblast-populated collagen lattices (FPCLs) were used as a model of contraction. FPCLs were allowed to develop mechanical stress (48 hours) during treatment with ilomastat (0-100 micromol/L), released, and allowed to contract over a 48-hour period. Contraction was estimated by measuring lattice area compared with untreated cells or treatment with a control peptide. MMP-1, MMP-2, and MT1-MMP levels were assessed by zymography, Western blotting, and enzyme-linked immunosorbent assay. RESULTS: Nodule-derived fibroblasts contracted lattices (69% +/- 2) to a greater extent than did cord-derived (55% +/- 3) or carpal ligament-derived (55% +/- 1) fibroblasts. Exposure to ilomastat led to significant inhibition of lattice contraction by all fibroblasts, although a reduction in lattice contraction by nodule-derived fibroblasts was most prominent (84% +/- 8). In addition, treatment with ilomastat led to a concomitant suppression of MMP-1 and MMP-2 activity, whereas MT1-MMP activity was found to be upregulated. CONCLUSIONS: Our results demonstrate that inhibition of MMP activity results in a reduction in extracellular matrix contraction by Dupuytren fibroblasts and suggest that MMP activity may be a critical target in preventing recurrent contracture caused by this disease.


Subject(s)
Dupuytren Contracture/pathology , Fibroblasts/drug effects , Indoles/pharmacology , Matrix Metalloproteinase Inhibitors , Aged , Cell Culture Techniques , Cell Proliferation/drug effects , Collagen , Enzyme-Linked Immunosorbent Assay , Female , Fibroblasts/metabolism , Humans , Hydroxamic Acids , Male , Middle Aged , Up-Regulation
3.
BMC Dev Biol ; 7: 124, 2007 Nov 07.
Article in English | MEDLINE | ID: mdl-17988375

ABSTRACT

BACKGROUND: It has been well established that human fetuses will heal cutaneous wounds with perfect regeneration. Insulin-like growth factors are pro-fibrotic fibroblast mitogens that have important roles in both adult wound healing and during development, although their relative contribution towards fetal wound healing is currently unknown. We have compared responses to IGF-I and -II in human dermal fibroblast strains derived from early gestational age fetal (<14 weeks) and developmentally mature postnatal skin to identify any differences that might relate to their respective wound healing responses of regeneration or fibrosis. RESULTS: We have established that the mitogenic response of fetal cells to both IGF-I and -II is much lower than that seen in postnatal dermal fibroblasts. Further, unlike postnatal cells, fetal cells fail to synthesise collagen in response to IGF-I, whereas they do increase synthesis in response to IGF-II. This apparent developmentally regulated difference in response to these related growth factors is also reflected in changes in the tyrosine phosphorylation pattern of a number of proteins. Postnatal cells exhibit a significant increase in phosphorylation of ERK 1 (p44) in response to IGF-I and conversely the p46 isoform of Shc on IGF-II stimulation. Fetal cells however only show a significant increase in an unidentified 100 kDa tyrosine-phosphorylated protein on stimulation with IGF-II. CONCLUSION: Dermal fibroblasts exhibit different responses to the two forms of IGF depending on their developmental maturity. This may relate to the developmental transition in cutaneous wound healing from regeneration to fibrosis.


Subject(s)
Cell Proliferation/drug effects , Fibroblasts/drug effects , Skin/drug effects , Somatomedins/pharmacology , Adaptor Proteins, Signal Transducing/metabolism , Blotting, Western , Cells, Cultured , Child , Child, Preschool , Collagen/metabolism , Dermis , Fetus/cytology , Fibroblasts/cytology , Fibroblasts/metabolism , Flow Cytometry , Humans , Immunoprecipitation , Insulin-Like Growth Factor I/pharmacology , Insulin-Like Growth Factor II/pharmacology , Mitogen-Activated Protein Kinase 3/metabolism , Phosphorylation/drug effects , Receptor, IGF Type 1/metabolism , Shc Signaling Adaptor Proteins , Skin/cytology , Skin/metabolism , Src Homology 2 Domain-Containing, Transforming Protein 1
4.
Rev Sci Instrum ; 78(12): 123108, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18163721

ABSTRACT

A time domain optical coherence tomography (OCT) system is described that uses mid-infrared light (6-8 microm). To the best of our knowledge, this is the first OCT system that operates in the mid-infrared spectral region. It has been designed to characterize bioengineered tissues in terms of their structure and biochemical composition. The system is based upon a free-space Michelson interferometer with a germanium beam splitter and a liquid nitrogen cooled HgCdTe detector. A key component of this work has been the development of a broadband quantum cascade laser source (InGaAs/AlInAs containing 11 different active regions of the three well vertical transition type) that emits continuously over the 6-8 microm wavelength range. This wavelength range corresponds to the so called "mid-infrared fingerprint region" which exhibits well-defined absorption bands that are specifically attributable to the absorbing molecules. Therefore, this technology provides an opportunity for optical coherence molecular imaging without the need for molecular contrast agents. Preliminary measurements are presented.


Subject(s)
Spectrophotometry, Infrared/instrumentation , Tomography, Optical Coherence/instrumentation , Equipment Design , Equipment Failure Analysis , Infrared Rays , Reproducibility of Results , Sensitivity and Specificity
5.
Ophthalmol Clin North Am ; 18(4): 539-59, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16314218

ABSTRACT

Significant advances have been made in developing new treatments and refining existing treatments for the prevention of scarring after disease, trauma, or surgical prevention. The advent of new technologies in addition to traditional chemical drugs such as dendrimers, antibodies, aptamers, ribozymes, gene therapy with viral vectors, and RNA interference, opens the door to a whole new generation of therapies to prevent fibrosis in the eye. The ability to control fibrotic processes in the eye offers many tantalizing prospects, including prevention of corneal blindness from scarring to "20/5 vision" with perfect corneal wound healing after wavefront refractive surgery prevention of PCO to fully accommodative lens implants, 100% success of glaucoma surgery with pressure at approximately 10 mmHg associated with < 5% progression over a decade, to no failure of retinal detachment surgery and minimal visual loss from AMD. Finally, most exciting is the prospect that neutralizing the fibrotic response to disease and injury will allow us to revert to the "fetal" mode when regeneration is the normal process, such as shown in the recent report that demonstrated that induction of bcl-2 gene expression together with downregulation of gliosis results in axonal regeneration in mice.


Subject(s)
Eye Diseases/prevention & control , Eye/pathology , Ophthalmologic Surgical Procedures/adverse effects , Animals , Eye Diseases/etiology , Eye Diseases/pathology , Fibrosis/etiology , Fibrosis/prevention & control , Humans , Postoperative Complications , Wound Healing
6.
Plast Reconstr Surg ; 116(1): 209-21; discussion 222-3, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15988270

ABSTRACT

BACKGROUND: Fibroproliferative disorders, such as Dupuytren's contracture of the hand, are characterized by excessive production of collagen. 5-Fluorouracil has been used to treat fibroproliferative disorders of the eye and skin and is thought to inhibit thymidylate synthetase blocking DNA replication. 5-Fluorouracil has been shown to down-regulate fibroblast proliferation and differentiation in vitro. METHODS: This study investigated the dose-dependent effect of 5-fluorouracil on fibroblast extracellular matrix production. Fibroblasts were derived from tendon and primary Dupuytren's disease of the hand, a fibroproliferative disorder of the palmar aponeurosis (n = 4 patients). Total collagen synthesis was determined by means of the incorporation of radiolabeled proline. Fibroblast secretion of the profibrotic factor transforming growth factor-beta1 (TGF-beta1) was measured by a sandwich enzyme-linked immunosorbent assay. Gene expression of collagen types I and III and TGF-beta1 were quantified by means of reverse-transcriptase polymerase chain reaction assays. RESULTS: The authors found that 5-fluorouracil caused a dose-dependent, selective, and specific decrease in collagen production by Dupuytren's fibroblasts compared with noncollagenous protein synthesis. By contrast, procollagen types I and III mRNA were unaffected by 5-fluorouracil treatment. These changes did not appear to be mediated by alterations in the endogenous secretion of TGF-beta1 or its autocrine effect on collagen metabolism. CONCLUSIONS: The clinical implication is that 5-fluorouracil could possibly reduce extracellular matrix production and therefore reduce recurrence of Dupuytren's disease of the hand.


Subject(s)
Antimetabolites/pharmacology , Collagen/biosynthesis , Dupuytren Contracture/metabolism , Fibroblasts/drug effects , Fluorouracil/pharmacology , Antimetabolites/administration & dosage , Antimetabolites/therapeutic use , Cells, Cultured , Dose-Response Relationship, Drug , Down-Regulation/physiology , Dupuytren Contracture/drug therapy , Extracellular Matrix Proteins/biosynthesis , Fluorouracil/administration & dosage , Fluorouracil/therapeutic use , Gene Expression/drug effects , Granulation Tissue/cytology , Humans , Reverse Transcriptase Polymerase Chain Reaction , Tendons/metabolism , Transcription, Genetic/drug effects , Transforming Growth Factor beta/metabolism , Transforming Growth Factor beta1
7.
Am J Pathol ; 166(5): 1555-63, 2005 May.
Article in English | MEDLINE | ID: mdl-15855654

ABSTRACT

Since the first description of matrix metalloproteinase (MMP)-1 as an interstitial collagenase, great importance has been ascribed to this enzyme in extracellular matrix remodeling during tumoral, inflammatory, and angiogenic processes. As more evidence for the role of MMPs in targeting nonmatrix substrates emerges, casual observations that intracellular MMP-1 is found in vitro and in vivo prompt investigation of the role that MMP-1 may play on basic cell functions such as cell division and apoptosis. Here we show for the first time that MMP-1 not only has extracellular functions but that it is strongly associated with mitochondria and nuclei and accumulates within the cells during the mitotic phase of the cell cycle. On induction of apoptosis, MMP-1 co-localized with aggregated mitochondria and accumulated around fragmented nuclei. Inhibition of this enzyme by RNA interference or treatment with a broad MMP inhibitor caused faster degradation of lamin A, activation of caspases, and fragmentation of DNA when compared with untreated cells. These observations strongly suggest that intracellular association of MMP-1 to mitochondria and nuclei confers resistance to apoptosis and may explain the well-known association of this enzyme with tumor cell survival and spreading.


Subject(s)
Apoptosis/physiology , Lamin Type A/metabolism , Matrix Metalloproteinase 1/physiology , Organelles/enzymology , Caspases/metabolism , Cell Cycle/physiology , Cell Nucleus/enzymology , Cells, Cultured , DNA Fragmentation , Enzyme Activation , Fibroblasts/enzymology , Gene Silencing , Humans , Matrix Metalloproteinase 1/genetics , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase Inhibitors , Mitochondria/enzymology , Mitosis , Pigment Epithelium of Eye/cytology , Pigment Epithelium of Eye/enzymology , Staurosporine/pharmacology , Tissue Distribution
8.
J Hand Surg Am ; 28(2): 221-30, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12671852

ABSTRACT

PURPOSE: The migratory response of surface fibroblasts to flexor tendon injury was studied by their selective labeling with a vital dye. METHOD: The surfaces of 30 rat deep flexor tendons were bathed in 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine percholate (DiI), a vital dye for 5 minutes. The residual dye was removed by thorough irrigation. A partial tenotomy was made in the stained section by cutting out a central window. Semiquantitative cell counts and position of stained fibroblasts were noted by examination under fluorescent light at 0, 1, 3, 5, and 7 days. RESULTS: The surface fibroblasts readily took up the vital dye at day 0. By day 1 dyed cells had moved into the cut. By day 3 they had migrated laterally into the core substance of the tendon. Core dyed cell counts at days 1, 3, 5, and 7 were significantly different compared with day 0 core dyed cell counts. CONCLUSIONS: This cell migration from the surface of the cut to the tendon core is likely to be vital in the early stages of tendon healing.


Subject(s)
Tendon Injuries/physiopathology , Tendons/physiology , Wound Healing/physiology , Animals , Carbocyanines , Cell Count , Fluorescent Dyes , Hindlimb , Histological Techniques , Male , Rats , Rats, Sprague-Dawley , Statistics, Nonparametric , Tendons/ultrastructure
9.
Invest Ophthalmol Vis Sci ; 44(3): 1104-10, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12601036

ABSTRACT

PURPOSE: To investigate the effect of matrix metalloproteinase (MMP) inhibition on fibroblast-mediated matrix contraction and production. METHODS: Free-floating fibroblast-populated type I collagen lattices were prepared with human Tenon's capsule fibroblasts. Lattice areas were photographed and digitally analyzed to indicate the degree of lattice contraction. Quantitative competitive reverse transcription-polymerase chain reaction (QCRT-PCR) and enzyme-linked immunosorbent assay (ELISA) were used to quantify mRNA and protein respectively for MMP-1, -2, and -3 by fibroblasts during lattice contraction. Gelatin zymography demonstrated activity of MMPs released into the conditioned medium of contracting lattices. Concentrations of the broad-spectrum MMP inhibitors ilomastat, CellTech (Slough, UK), and BB-94 were added to the contracting fibroblast-populated collagen lattices. Secreted C-terminal propeptide of type I collagen was measured in conditioned medium of contracting lattices by ELISA. Fibroblast proliferation in the presence of concentrations of ilomastat was measured by using the reagent water-soluble tetrazolium-1 (WST-1). RESULTS: During contraction of type I collagen lattices, Tenon's capsule fibroblasts expressed MMP-1, -2, and -3 mRNA and protein. Zymography demonstrated the release of four gelatinolytic species into the conditioned medium of contracting lattices (57, 72, 91, and 100 kDa). Inclusion of MMP inhibitors in the zymogram-developing buffer reduced the proteolytic activity of the detected bands. MMP inhibition (1-100 microM) significantly reduced fibroblast-mediated collagen lattice contraction (P < 0.05), and this effect was found to be reversible. Ilomastat also significantly inhibited production of collagen in a dose-dependent manner (P < 0.05). No effect on fibroblast proliferation was found in the presence of ilomastat. CONCLUSIONS: MMPs are produced during Tenon's capsule fibroblast-mediated collagen lattice contraction. Broad-spectrum MMP inhibition significantly reduced matrix contraction and production without cell toxicity. Future clinical use of MMP inhibitors may be possible, because MMP inhibition significantly reduces fibroblast functions associated with contractile scarring.


Subject(s)
Collagen Type I/biosynthesis , Fibroblasts/metabolism , Matrix Metalloproteinase Inhibitors , Phenylalanine/analogs & derivatives , Protease Inhibitors/pharmacology , Cell Division , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Fibroblasts/drug effects , Humans , Hydroxamic Acids , Indoles/pharmacology , Matrix Metalloproteinases/genetics , Matrix Metalloproteinases/metabolism , Phenylalanine/pharmacology , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Thiophenes/pharmacology
10.
J Invest Dermatol ; 121(5): 1145-9, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14708618

ABSTRACT

We have investigated the expression of P2X5, P2X7, P2Y1, and P2Y2 receptor subtypes in 8- to 11-wk-old human fetal epidermis in relation to markers of proliferation (proliferating cell nuclear antigen (PCNA) and Ki-67), keratinocyte differentiation (cytokeratin K10 and involucrin), and markers of apoptosis (TdT-mediated dUTP nick end labeling (TUNEL) and anti-caspase-3). Immunohistochemistry showed that each of the four receptors was expressed in spatially distinct zones of the developing epidermis: P2Y1 receptors were found in the basal layer, P2X5 receptors were predominantly in the basal and intermediate layers, and both P2Y2 and P2X7 receptors were in the periderm. Colocalization experiments suggested different functional roles for these receptors. P2Y1 receptors were found in fetal keratinocytes positive for PCNA and Ki-67, suggesting a role in proliferation. P2X5 receptors double labeled with differentiated fetal keratinocytes that were positive for cytokeratin K10, suggesting a role in differentiation. P2X7 receptors colocalized with anti-caspase-3 antibody and were also expressed in periderm cells positive for TUNEL, suggesting a role in periderm cell apoptosis. P2Y2 receptors were found only in periderm cells and may have a role in chloride and fluid secretion into the amniotic fluid.


Subject(s)
Apoptosis , Epidermal Cells , Epidermis/embryology , Keratinocytes/physiology , Receptors, Purinergic P2/physiology , Signal Transduction/physiology , Cell Differentiation , Cell Division , Fetus/cytology , Humans , Immunohistochemistry , Receptors, Purinergic P2/analysis , Receptors, Purinergic P2X5 , Receptors, Purinergic P2X7 , Receptors, Purinergic P2Y1 , Receptors, Purinergic P2Y2
SELECTION OF CITATIONS
SEARCH DETAIL
...